On May 15, 2026, Saturn V Capital Management disclosed the sale of 822,007 shares of Dyne Therapeutics, valued at approximately $14.17 million. Following the sale, Dyne accounted for 3.17% of Saturn V’s assets, with the firm holding nearly 1 million shares at quarter’s end. Dyne Therapeutics, focused on developing treatments for rare muscle diseases, reported encouraging updates regarding its investigational drug and a strong cash position of $972.2 million to support operations until early 2028. The company is navigating significant expectations as it aims for successful commercial execution after promising clinical trials.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/coverage/filings/2026/05/19/dyne-therapeutics-is-up-40-but-one-biotech-fund-just-disclosed-selling-usd14-million-worth-of-shares/
